Minerva Neurosciences Files 8-K with Key Corporate Updates
Ticker: NERV · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1598646
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance
Related Tickers: MINV
TL;DR
MINV files 8-K: material agreement, equity sales, bylaws change, FD disclosure, financials. Big moves happening.
AI Summary
Minerva Neurosciences, Inc. filed an 8-K on October 22, 2025, reporting on events as of October 21, 2025. The filing indicates entry into a material definitive agreement, unregistered sales of equity securities, amendments to articles of incorporation or bylaws, and Regulation FD disclosures. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing signals significant corporate actions by Minerva Neurosciences, including potential new agreements and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity securities and amendments to corporate documents, which can introduce regulatory and financial risks.
Key Players & Entities
- Minerva Neurosciences, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- October 22, 2025 (date) — Filing date
- 1500 District Avenue, Burlington, MA 01803 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Minerva Neurosciences?
The filing indicates entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
What specific amendments were made to the articles of incorporation or bylaws?
The filing notes amendments to articles of incorporation or bylaws, but the exact nature of these amendments is not specified in the provided text.
What is the primary business of Minerva Neurosciences, Inc. according to its SIC code?
Minerva Neurosciences, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When does Minerva Neurosciences, Inc. typically end its fiscal year?
Minerva Neurosciences, Inc.'s fiscal year ends on December 31st.
Filing Stats: 3,861 words · 15 min read · ~13 pages · Grade level 17 · Accepted 2025-10-21 20:25:10
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NERV The Nasdaq
- $1,000 — eferred Stock"), at a purchase price of $1,000 per share, (ii) tranche A warrants (the
- $200 m — or an aggregate offering price of up to $200 million, as further described below. The
- $80 million — for an aggregate cash exercise price of $80 million until the tenth day following the date
- $40 million — for an aggregate cash exercise price of $40 million commencing on the earlier of (i) the Co
- $2.11 — ommon Stock, at the conversion price of $2.11 per share, rounded down to the nearest
Filing Documents
- d28380d8k.htm (8-K) — 55KB
- d28380dex31.htm (EX-3.1) — 83KB
- d28380dex41.htm (EX-4.1) — 54KB
- d28380dex42.htm (EX-4.2) — 61KB
- d28380dex101.htm (EX-10.1) — 259KB
- d28380dex102.htm (EX-10.2) — 19KB
- d28380dex991.htm (EX-99.1) — 23KB
- g28380g1021152028870.jpg (GRAPHIC) — 4KB
- 0001193125-25-245552.txt ( ) — 825KB
- nerv-20251021.xsd (EX-101.SCH) — 3KB
- nerv-20251021_lab.xml (EX-101.LAB) — 18KB
- nerv-20251021_pre.xml (EX-101.PRE) — 11KB
- d28380d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock 4.1 Form of Preferred Tranche A Warrant 4.2 Form of Preferred Tranche B Warrant 10.1* Form of Securities Purchase Agreement, dated October 21, 2025, by and among Minerva Neurosciences, Inc. and the purchasers named therein 10.2* Form of Support Agreement 99.1 Press release dated October 21, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request. Forward-Looking Safe Harbor Statement This Current Report on Form 8-K contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of hereof, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the aggregate amount of proceeds to be received from the Private Placement, the closing of the Private Placement, and the anticipated use of proceeds from the Private Placement; and the appointment of three additional directors with significant schizophrenia clinical trial experience and formation of the SAB. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, the factors that are described under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its Annual Re
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2025 MINERVA NEUROSCIENCES, INC. /s/ Remy Luthringer Remy Luthringer Chief Executive Officer